EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia

Gabriela Nestal de Moraes, Paloma Silva Souza, Fernanda Casal de Faria Costas, Flavia Cunha Vasconcelos, Flaviana Ruade Souza Reis, Raquel Ciuvalschi Maia

Leukemia Research and Treatment · 2012

DOI: 10.1155/2012/671702 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia Research and Treatment, 2012. Verfasst von Gabriela Nestal de Moraes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Hemato-Oncologia Celular e Molecular, Programa de Pesquisa em Hemato-Oncologia Molecular, Instituto Nacional de Câncer (INCA), Praça d…. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 208 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic myeloid leukemia (CML) is a clonal hematopoietic disorder characterized by the presence of the Philadelphia chromosome which resulted from the reciprocal translocation between chromosomes 9 and 22. The pathogenesis of CML involves the constitutive activation of the BCR-ABL tyrosine kinase, which governs malignant disease by activating multiple signal transduction pathways. The BCR-ABL kinase inhibitor, imatinib, is the front-line treatment for CML, but the emergence of imatinib resistance and other tyrosine kinase inhibitors (TKIs) has called attention for additional resistance mechanisms and has led to the search for alternative drug treatments. In this paper, we discuss our current understanding of mechanisms, related or unrelated to BCR-ABL, which have been shown to account for chemoresistance and treatment failure. We focus on the potential role of the influx and efflux transporters, the inhibitor of apoptosis proteins, and transcription factor-mediated signals as feasible molecular targets to overcome the development of TKIs resistance in CML.

Autor:innen und Institutionen

  • Laboratório de Hemato-Oncologia Celular e Molecular, Programa de Pesquisa em Hemato-Oncologia Molecular, Instituto Nacional de Câncer (INCA), Praça da Cruz Vermelha 23, 6° andar, Centro, 20230-130 Rio de Janeiro, RJ, Br…

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

Zitieren

APA

Nestal de Moraes, G., Souza, P. S., Costas, F. C., Vasconcelos, F. C., Reis, F. R., & Maia, R. C. (2012). The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia. Leukemia Research and Treatment. https://doi.org/10.1155/2012/671702

Vancouver

Nestal de Moraes G, Souza PS, Costas FC, Vasconcelos FC, Reis FR, Maia RC. The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia. Leukemia Research and Treatment. 2012. doi:10.1155/2012/671702

BibTeX
@article{NestaldeMoraes2012,
  author = {Nestal de Moraes, Gabriela and Souza, Paloma Silva and Costas, Fernanda Casal de Faria and Vasconcelos, Flavia Cunha and Reis, Flaviana Ruade Souza and Maia, Raquel Ciuvalschi},
  title = {The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia},
  journal = {Leukemia Research and Treatment},
  year = {2012},
  doi = {10.1155/2012/671702}
}
Kostenlos starten →